Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons JM van den Eertwegh(Amsterdam UMC Location Vrije Universiteit Amsterdam), Winald R. Gerritsen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Saskia J. Santegoets(Amsterdam UMC Location Vrije Universiteit Amsterdam), R. Jeroen A. van Moorselaar(Amsterdam UMC Location Vrije Universiteit Amsterdam), H. Pieter van den Berg(Amsterdam UMC Location Vrije Universiteit Amsterdam), Kristen Hege(University of California, San Francisco), Tim M. van der Sluis(Amsterdam UMC Location Vrije Universiteit Amsterdam), Tanja D. de Gruijl(Dutch Cancer Society), Karin Jooss(Unknown), Natalie Sacks(Genesys (United States)), Anita G.M. Stam(Vrije Universiteit Amsterdam), Herbert M. Pinedo(Leiden University), B. Mary E. von Blomberg(Vrije Universiteit Amsterdam), Helen Gall(University of Amsterdam), Thomas C. Harding(Genesys (United States)), Jurjen Versluis(Erasmus MC), Rik J. Scheper(Unknown), Israel Lowy(Bristol-Myers Squibb (Germany))
Cited by 357
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Fluorouracil: biochemistry and pharmacology.
|Journal of Clinical Oncology|1988|834